Bruker (NASDAQ:BRKR) Issues Earnings Results

Bruker (NASDAQ:BRKR) issued its earnings results on Tuesday. The medical research company reported $0.60 EPS for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01), Briefing.com reports. The company had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 24.92% and a net margin of 11.29%. Bruker’s revenue was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.74 earnings per share. Bruker updated its FY 2024 guidance to 2.360-2.410 EPS and its FY24 guidance to $2.36-2.41 EPS.

Bruker Stock Performance

BRKR stock traded up $1.83 during midday trading on Thursday, hitting $60.81. 328,520 shares of the stock traded hands, compared to its average volume of 1,068,068. The firm has a market cap of $9.21 billion, a P/E ratio of 24.47, a PEG ratio of 2.32 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. The stock’s fifty day simple moving average is $63.97 and its 200-day simple moving average is $66.51. Bruker has a 1-year low of $54.55 and a 1-year high of $94.86.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Wells Fargo & Company dropped their target price on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research note on Wednesday. Wolfe Research downgraded shares of Bruker from an “outperform” rating to a “peer perform” rating in a research note on Monday, September 30th. TD Cowen lowered their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research report on Wednesday. Citigroup lowered their price target on shares of Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Barclays lowered their price target on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research report on Wednesday. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Bruker has a consensus rating of “Moderate Buy” and a consensus price target of $79.36.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.